Results 21 to 30 of about 20,461 (225)

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes

ESC Heart Failure, 2023
Aims The relationship between diabetic microvascular complications and the incidence of two types of heart failure—heart failure with reduced ejection fraction (HFrEF) (left ventricular ejection fraction [LVEF] 
Mayu Tochiya, Hisashi Makino, Tamiko Tamanaha, Yoko Omura‐Ohata, Masaki Matsubara, Ryo Koezuka, Michio Noguchi, Tsutomu Tomita, Yasuhide Asaumi, Yoshihiro Miyamoto, Satoshi Yasuda, Kiminori Hosoda   +11 more
doaj   +1 more source

Chronic Kidney Disease Increases Risk of Incident HFrEF Following Percutaneous Coronary Intervention

Frontiers in Cardiovascular Medicine, 2022
BackgroundChronic kidney disease (CKD) is very common in patients who are at a high risk of developing incident heart failure with reduced ejection fraction (HFrEF).
Wenguang Lai, Wenguang Lai, Wenguang Lai, Xiaoli Zhao, Sijia Yu, Sijia Yu, Sijia Yu, Ziling Mai, Ziling Mai, Ziling Mai, Yang Zhou, Yang Zhou, Zhidong Huang, Zhidong Huang, Qiang Li, Qiang Li, Haozhang Huang, Haozhang Huang, Haozhang Huang, Huanqiang Li, Huanqiang Li, Haiyan Wei, Dachuan Guo, Yun Xie, Yun Xie, Yun Xie, Shanggang Li, Shanggang Li, Hongyu Lu, Hongyu Lu, Jin Liu, Jin Liu, Shiqun Chen, Shiqun Chen, Yong Liu, Yong Liu, Yong Liu   +36 more
doaj   +1 more source

Mechanisms of sacubitril–valsartan benefit in HFrEF [PDF]

Nature Reviews Cardiology, 2019
Two studies reveal new details of the mechanisms underlying the benefits of the angiotensin receptor–neprilysin inhibitor sacubitril–valsartan in patients with heart failure and reduced ejection fraction, suggesting that sacubitril–valsartan induces reverse cardiac remodelling but has no effect in reducing central aortic stiffness.
openaire   +2 more sources

Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis

Brazilian Journal of Medical and Biological Research
Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have symptoms and signs of HF with normal or near-normal left ventricular ejection fraction (LVEF ≥50%).
Chao Ma, Huan Luo, Lei Fan, Xiaoyan Liu, Chengshan Gao   +4 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Consequences of group III/IV afferent feedback and respiratory muscle work on exercise tolerance in heart failure with reduced ejection fraction

Experimental Physiology, 2023
Exercise intolerance and exertional dyspnoea are the cardinal symptoms of heart failure with reduced ejection fraction (HFrEF). In HFrEF, abnormal autonomic and cardiopulmonary responses arising from locomotor muscle group III/IV afferent feedback is one
Joshua R. Smith, Jonathon W. Senefeld, Kathryn F. Larson, Michael J. Joyner   +3 more
doaj   +1 more source

Lower AKI Risk and Higher Survival With Microaxial Flow Pump Support During Elective PCI: A Propensity Score‐Matched Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Acute kidney injury (AKI) is associated with worse outcomes after percutaneous coronary intervention (PCI). Previous, smaller studies suggested nephroprotective effects of micro‐axial flow pump (mAFP) during PCI. This study aimed to compare renal outcomes of high‐risk PCI with mAFP or intraaortic balloon pump (IABP) support.
Elric Zweck, Andrew Shaw, Amin Polzin, Nudrat Noor, Sathya Unudurthi, Michael Cuchiara, Kai M. Schmidt‐Ott, Malte Kelm, Ralf Westenfeld, Rafael Kramann, Ravindra L. Mehta   +10 more
wiley   +1 more source

Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future

Reviews in Cardiovascular Medicine
This review aims to summarize the status and future directions of pediatric heart failure (HF) pharmacotherapy. Notably, managing HF in children presents unique challenges due to heterogeneous etiologies and a longstanding paucity of pediatric-specific ...
Bibhuti B Das
doaj   +1 more source

Coronary Flow in Hypertrophic Obstructive Cardiomyopathy—Immediate Effects of Alcohol Septal Ablation

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Hypertrophic cardiomyopathy is associated with alterations in coronary microvascular function which have variable pathophysiologic mechanisms, and variable reversibility acutely and chronically following alcohol septal ablation (ASA).
Vojko V. Misevic, Ana N. Golocevac, Kosta S. Krupnikovic, Stefan B. Timcic, Natalija B. Arnautovic, Dragana D. Radoicic, Milan R. Dobric, Aleksandar D. Mandic, Stefan S. Zivkovic, Aleksa D. Obradovic, Vladimir D. Mihajlovic, Natalija R. Odanovic, Ivan S. Ilic   +12 more
wiley   +1 more source

Ivabradine in Heart Failure with Reduced Ejection Fraction (HFrEF): A Narrative Review of Clinical Outcomes

Jurnal Manajemen dan Pelayanan Farmasi
Background: Therapy for heart failure with reduced ejection fraction (HFrEF) patients is complex, involving several combinations of treatments, but there are still some problems, such as rehospitalization, reduced ejection fraction values, increased ...
Rizky Hidayaturahmah, Erin Khoerunisa, Nisa Yulianti Suprahman, Fia Novitasari   +3 more
doaj   +1 more source